Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Overweight rating and announces Price Target of $2.
A big investment bank just started following Ensysce Biosciences and thinks it looks good. When experts start watching a smaller company, it means they see something worth paying attention to.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.